VarmX Appoints John Glasspool as CEO to Lead New Growth Phase
Portfolio - People | Nov 11, 2024 | Biogeneration Ventures (BGV)
VarmX, a pioneer in developing therapies for bleeding disorders, has appointed John Glasspool as its new CEO. Glasspool brings over 30 years of experience in the biopharma sector, having served as CEO of Anthos Therapeutics, where he enabled significant fundraising and the expansion into critical clinical trials. His appointment is strategic for VarmX as it looks to forward its lead asset, VMX-C001, which targets urgent care needs in coagulation therapies. VarmX, a spin-out from Leiden University Medical Center, is entering its next growth phase, marked by a Series C fundraise and pivotal clinical trials. It operates with support from a consortium of investors including BioGeneration Ventures, signaling continued confidence in its innovative approaches to medical therapies.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital/Private Equity
Geography
- The Netherlands – VarmX is headquartered in Leiden, The Netherlands, reflecting the geographical focus of the company's operations.
- United States – John Glasspool has held roles in the US, and his experience includes engagements with various US-based biopharma organizations, indicating his involvement spans international borders.
Industry
- Biotechnology – VarmX is a biotech company developing therapies for bleeding disorders, reflecting the core focus of the biopharmaceutical industry.
- Pharmaceuticals – The involvement of John Glasspool, with his background in major pharmaceutical companies and therapeutic development, aligns with the pharmaceutical sector.
- Venture Capital/Private Equity – BioGeneration Ventures is a key investor in VarmX, highlighting the role of venture capital in funding biotech advancements.
Financials
- Series C Fundraise – Upcoming fundraising initiative to support VarmX's clinical development and expansion efforts.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| VarmX | Biotech Company | Company | A biotech firm focused on innovative coagulation disorder therapies, particularly for patients on anticoagulation therapy. |
| John Glasspool | CEO | Person | Newly appointed CEO of VarmX, previously CEO of Anthos Therapeutics, bringing over 30 years of biopharma experience. |
| BioGeneration Ventures | Investor | Company | A venture capital firm and key investor in VarmX, providing financial support for developing innovative bioscience solutions. |
| Leiden University Medical Center | Founding Institution | Company | The academic institution from which VarmX was spun out, known for its research in hemostasis and thrombosis. |
| EQT Life Sciences | Investor | Company | One of the investors supporting VarmX in its biotech ventures. |
| Sound Bioventures | Investor | Company | Part of the investor syndicate backing VarmX. |
| InnovationQuarter | Investor | Company | Regional development agency investing in VarmX's advancements. |
| EIC | Investor | Company | European investor supporting VarmX. |